TITLE:
Microalbuminuria and Kidney Disease Risk in HIV Patients Taking Combined Antiretroviral Therapy
AUTHORS:
Huylmer Lucena Chaves, Mayanna Pinho Batista, Adriana de Menezes Gomes, Amanda Antunes Costa, André Tigre Lima, Vinícius Diniz Arcelino do Ceará, Pedro Rubens Araújo Carvalho, Linna Albuquerque Sampaio, Fabrício de Maicy Bezerra, Melissa Soares Medeiros
KEYWORDS:
HIV, AIDS, Antiretroviral, Kidney Disease, Microalbuminuria
JOURNAL NAME:
World Journal of AIDS,
Vol.4 No.2,
June
25,
2014
ABSTRACT: Objectives: This study
proposes to evaluate risk factors for kidney disease in HIV patients treated
chronically and correlate with microalbuminuria measurements. Methods: Review
charts and analyses of microalbuminuria in subgroup of HIV patients treated at
Ceara/Brazil. Results: 149 patients, 69.1% male, mean 38.5 years old, infection
mean 86.8 months. Mean Creatinine Clearance 110.2%, Creatinine 0.97, Urea 27.76
mg/dl, CD4+ 600.37 cels/mm3 and detectable viral load 530.59 copies
with 61.7% undetectable. Mean Dosages of microalbuminuria/24h 147, 46 ± 820, 45
(N = 48) and microalbuminuria (mg/dl) 32.05 ± 85.25 (N = 43). Kidney Diseases
Classification analyses evidenced 6.4%
patients in stages ≥3 and 6.2% presented altered Microalbuminuria/24h. Patients
using Tenofovir (TDF) 27.27% had Stage 2 and protease inhibitors (PI) had 4.1%
in Stage 3. Proteinuria was observed in 5% stage ≥3. Association PI/TDF had
4.1% in Stage 3. No statistical difference between CD4 > or 3 and microalbuminuria/24h > 300 mg (p = 0.69); detectable/undetectable viral
load and microalbuminuria/24h (p = 0.63) or stage ≥3 (p = 0.17); relation to
Diabetes or arterial hypertension and microalbuminuria 24 h (p = 0.5 and p = 0.21);
relation stage ≥3 and microalbuminuria/24h (p = 0.33); relation HIV diagnoses
>/> or
or